Meeting
2020 ASCO Virtual Scientific Program
Clinicopathologic features and outcomes of de novo transformed indolent lymphoma.
Authors
Collin K Chin
The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX
Collin K Chin , Chan Cheah , Preetesh Jain , Nathan Hale Fowler , Luis Fayad , Jason Westin , Maria Alma Rodriguez , Mansoor Noorani , Sattva Swarup Neelapu , Fredrick B. Hagemeister Jr., L Jeffrey Medeiros , Francisco Vega , Felipe Samaniego , Christopher Flowers , Loretta J. Nastoupil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8061)
DOI
10.1200/JCO.2020.38.15_suppl.8061
Abstract #
8061
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).
First Author: Ruemu Ejedafeta Birhiray
Poster
2022 ASCO Annual Meeting
inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
First Author: Laurie Helen Sehn
Poster
2021 ASCO Annual Meeting
Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).
First Author: Wojciech Jurczak
Poster
2020 ASCO Virtual Scientific Program
Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).
First Author: Gerhard Held